Work

Treatment switching between Enzalutamide and Abiraterone Acetate and time to oral opioid initiation in castration-resistant prostate cancer patients

Year: 2025

Type: article

Study design: Observational Study

Source: Cancer Epidemiology

DOI: 10.1016/j.canep.2025.102769

Authors: Ibrahim M. Asiri, Ronald C. Chen, Viraj Master, Lanyu Mi, Sarah E. James, Folakemi T. Odedina, Alan H. Bryce, Jon C. Tilburt, Irbaz B. Riaz, Syed Arsalan Ahmed Naqvi, Veronica Abraham, Steven R.H. Beach, Ewan K. Cobran

Institutions: Mayo Clinic, Mayo Clinic in Arizona, Saudi Food and Drug Authority, University of Kansas, The University of Kansas Health System, University of Kansas Medical Center, Emory University, Mayo Clinic Hospital, Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Florida), City of Hope, American College of Medical Genetics, University of Georgia

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Cancer Institute, National Center for Advancing Translational Sciences

Awards: Genetic Literacy and Patient-Caregiver Communication of Prognostic Genetic Technology for Localized Prostate Cancer, Georgia Clinical & Translational Science Alliance (Georgia CTSA)

OpenAlex ID: W4407407735

FWCI: 0.657

Cites: 31

Cited by: 1

Related to: 10